A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma

Shin Ichi Takemura, Toshio Kudo, Ryutaro Asano, Masanori Suzuki, Kouhei Tsumoto, Naoki Sakurai, Yu Katayose, Hideaki Kodama, Hiroshi Yoshida, Shinji Ebara, Hisaaki Saeki, Kohzoh Imai, Seiki Matsuno, Izumi Kumagai

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

In cancer immunotherapy research, many bispecific antibodies (BsAbs) have been developed for directing T cells toward tumor cells. Recent advances in genetic engineering have made it possible to prepare immunoglobulin fragments consisting of variable domains using bacterial expression systems. Therefore, recombinant BsAbs, termed diabodies, have attracted particular attention. We have previously produced an anti-MUC1 x anti-CD3 diabody (Mx3 diabody) in an Escherichia coli (E. coli) expression system. In order to reinforce the antitumor effects of the Mx3 diabody, mutated superantigen staphylococcal enterotoxin A (SEA) D227A was genetically fused to the Mx3 diabody. The SEA D227A fusion Mx3 diabody (SEA D227A-Mx3 diabody) thus constructed showed remarkable MUC1-specific antitumor effects when used with effector cells (lymphokine-activated killer cells with T-cell phenotype [T-LAK] and peripheral blood mononuclear cells [PBMCs]). In the bile duct carcinoma (BDC)-xenografted severe combined immunodeficient (SCID) mouse model, it also demonstrated strong antitumor activity when administered i.v. together with T-LAK cells and interleukin-2 (IL-2). In this experiment, the complete disappearance of tumors was observed in 3 out of 6 mice, and the other 3 showed marked retardation of tumor growth. Therefore, the SEA D227A-Mx3 diabody is considered to be a promising reagent in specific targeted immunotherapy for BDC and other MUC1- positive carcinomas. This is the first report on a diabody that is effective in treating human solid cancers in the xenografted SCID mouse experimental model.

Original languageEnglish
Pages (from-to)33-44
Number of pages12
JournalCancer Immunology, Immunotherapy
Volume51
Issue number1
DOIs
Publication statusPublished - 2002 Feb 28

Keywords

  • Diabody
  • MUC1
  • Refolding system
  • Second-generation bispecific antibody
  • Superantigen

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Takemura, S. I., Kudo, T., Asano, R., Suzuki, M., Tsumoto, K., Sakurai, N., Katayose, Y., Kodama, H., Yoshida, H., Ebara, S., Saeki, H., Imai, K., Matsuno, S., & Kumagai, I. (2002). A mutated superantigen SEA D227A fusion diabody specific to MUC1 and CD3 in targeted cancer immunotherapy for bile duct carcinoma. Cancer Immunology, Immunotherapy, 51(1), 33-44. https://doi.org/10.1007/s00262-001-0245-3